| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | -0.065 | 0.08 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | -0.089 | 0.08 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.066 | 0.08 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.08 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.077 | 0.08 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | 0.058 | 0.09 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.09 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.09 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.09 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.06 | 0.09 |